Experience with the use of trastuzumab deruxtecan in real-world clinical practice: data from Clinical Oncology Dispensary no. 1 (Krasnodar) and Federal Scientific Clinical Center of the fMBA of Russia

This article presents a systematic review of international and domestic experience with the use of trastuzumab deruxtecan in patients with HER2-positive and HER2-low metastatic breast cancer. Based on an analysis of key registration studies (DESTINY-Breast01, -03, -04), and confirmatory clinical trials (DESTINY-Breast02, -12) and real-world clinical practice data from the Clinical Oncology Dispensary No. 1 (Krasnodar) (n = 22) and Federal Scientific Clinical Center of the Federal Medical and Biological Agency of Russia (n = 6), the article summarizes the specifics of drug administration in the Russian healthcare setting, its efficacy profile, and manageable toxicity. A clinical case of a patient with HER2-positive mBC and brain metastases is described in detail, demonstrating long-term disease control (more than 15 months) with trastuzumab deruxtecan therapy in the second line after progression during treatment with a combination of trastuzumab, pertuzumab, and docetaxel. Practical recommendations for clinicians on monitoring the key adverse event – interstitial lung disease and pneumonitis – have been formulated.

1. Malignant tumors in Russia in 2023 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shakhzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2024. 276 p. (In Russ.).

2. Bray F., Laversanne M., Sung H. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74(3): 229–63. DOI: 10.3322/caac.21834

3. Davydov M.I., Gantsev Sh.Kh. Oncology: textbook. Moscow: GEOTAR-Media, 2013. 912 p. (In Russ.).

4. Iqbal N., Iqbal N. Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int 2014;2014:852748. DOI: 10.1155/2014/852748

5. Tapia M., Hernando C., Martínez M.T. et al. Clinical impact of new treatment strategies for HER2-positive metastatic breast cancer patients with resistance to classical anti-HER therapies. Cancers (Basel) 2023;15(18):4522. Published 2023 Sep 12. DOI: 10.3390/cancers15184522

6. Swain S.M., Baselga J., Kim S.B. et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015;372(8):724–34.DOI: 10.1056/NEJMoa1413513

7. Premji S.K., O'Sullivan C.C. Standard-of-care treatment for HER2+ metastatic breast cancer and emerging therapeutic options. Breast Cancer (Auckl) 2024;18:11782234241234418. Published 2024 Feb 25. DOI: 10.1177/11782234241234418

8. SmPC data sheet for Enhertu, 100 mg, lyophilisate for the preparation of a concentrate for the preparation of an infusion solution. LP No. (001242)-(РГ-RU) dated July 16, 2026. Available: https://lk.regmed.ru/Register/EAEU_SmPC (date of access: August 15, 2026). (In Russ.).

9. Ogitani Y., Aida T., Hagihara K. et al. DS-8201a, a novel HER2targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res 2016;22(20):5097–108. DOI: 10.1158/1078-0432.CCR-15-2822

10. Ogitani Y., Hagihara K., Oitate M. et al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci 2016;107(7):1039–46. DOI: 10.1111/cas.12966

11. Modi S., Saura C., Yamashita T. et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med 2020;382(7):610–21. DOI: 10.1056/NEJMoa1914510

12. Cortés J., Kim S.B., Chung W.P. et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med 2022;386(12):1143–54. DOI: 10.1056/NEJMoa2115022

13. Hurvitz S.A., Hegg R., Chung W.P. et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet 2023;401(10371):105–17. DOI: 10.1016/S0140-6736(22)02420-5

14. Im S.A. Presented at: San Antonio Breast Cancer Symposium (SABCS) 2025; December 9–12, 2025; San Antonio, TX, USA. Poster PS5-01-30.

15. Yamashita T., Sohn J.H., Tokunaga E. et al. Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study. Breast Cancer 2024;31(5):858–68. DOI: 10.1007/s12282-024-01600-7

16. Harbeck N., Ciruelos E., Jerusalem G. et al. Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial. Nat Med 2024;30(12):3717–27. DOI: 10.1038/s41591-024-03261-7

17. Han Y., Wu Y., Xu H. et al. The impact of hormone receptor on the clinical outcomes of HER2-positive breast cancer: a population-based study. Int J Clin Oncol 2022;27(4):707–16. DOI: 10.1007/s10147-022-02115-x

18. Ran R., Zhao S., Zhou Y. et al. Clinicopathological characteristics, treatment patterns and outcomes in patients with HER2-positive breast cancer based on hormone receptor status: a retrospective study. BMC Cancer 2024;24(1):1216. Published 2024 Sep 30. DOI: 10.1186/s12885-024-12974-4

19. Hurvitz S.A., Kim S.B., Chung W.P. et al; Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial. ESMO Open 2024;9(5):102924. DOI: 10.1016/j.esmoop.2024.102924

20. Niikura N., Yamanaka T., Nomura H. et al. Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM). NPJ Breast Cancer 2023;9(1):82. DOI: 10.1038/s41523-023-00584-5.

21. Tyulyandin S.A., Artamonova E.V., Zhigulev A.N. et al. Breast cancer. RUSSCO clinical guidelines, part 1.2. Zlokachestvennyye opukholi = Malignant Neoplasms 2025;15(3s2):35–83. (In Russ.). DOI: 10.18027/2224-5057-2025-15-3s2-1.2-01

22. ROOM. Clinical guidelines. Gold standard for prevention, diagnosis, treatment, and rehabilitation of patients with breast cancer. Available at: https://docs.google.com/document/d/14XU19rSHmmg0v8aL9msY9B1uoscVK7WS/edit#heading=h.gjdgxs. (In Russ.).

23. Gradishar W.J., Moran M.S., Abraham J. et al. Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2024;22(5):331–57. DOI: 10.6004/jnccn.2024.0035

24. Gennari A., André F., Barrios C.H. et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol 2021;32(12):1475–95. DOI: 10.1016/j.annonc.2021.09.019